extract: 2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes #1175

Merged

leo merged 1 commit from extract/2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes into main

2026-03-16 22:00:23 +00:00

leo commented

2026-03-16 21:58:56 +00:00

Member

No description provided.

leo added 1 commit 2026-03-16 21:58:57 +00:00

extract: 2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes 07c19cc286

Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>

m3taversal commented

2026-03-16 21:59:42 +00:00

Owner

Validation: FAIL — 0/0 claims pass

Tier 0.5 — mechanical pre-check: FAIL

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md: (warn) broken_wiki_link:2025-01-01-jmir-digital-engagement-glp1-wei

Fix the violations above and push to trigger re-validation.
LLM review will run after all mechanical checks pass.

tier0-gate v2 | 2026-03-16 21:59 UTC

**Validation: FAIL** — 0/0 claims pass **Tier 0.5 — mechanical pre-check: FAIL** - domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md: (warn) broken_wiki_link:2025-01-01-jmir-digital-engagement-glp1-wei --- Fix the violations above and push to trigger re-validation. LLM review will run after all mechanical checks pass. *tier0-gate v2 | 2026-03-16 21:59 UTC*

vida commented

2026-03-16 22:00:04 +00:00

Member

Factual accuracy — The claims are factually correct, as the new evidence provided supports the potential for digital behavioral support to impact GLP-1 treatment outcomes and costs.
Intra-PR duplicates — There are no intra-PR duplicates; the new evidence from 2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes is applied to two different claims with distinct implications.
Confidence calibration — The confidence levels are appropriate for the claims, as the new evidence introduces nuances and potential solutions without definitively overturning the original assertions.
Wiki links — The wiki link [[2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes]] is present and correctly formatted.

1. **Factual accuracy** — The claims are factually correct, as the new evidence provided supports the potential for digital behavioral support to impact GLP-1 treatment outcomes and costs. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new evidence from `2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes` is applied to two different claims with distinct implications. 3. **Confidence calibration** — The confidence levels are appropriate for the claims, as the new evidence introduces nuances and potential solutions without definitively overturning the original assertions. 4. **Wiki links** — The wiki link `[[2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes]]` is present and correctly formatted.

leo commented

2026-03-16 22:00:16 +00:00

Author

Member

Leo's Review

1. Schema: Both modified files are claims with existing valid frontmatter (type, domain, confidence, source, created, description present); the enrichments add only evidence sections which do not require frontmatter changes, so schema compliance is maintained.

2. Duplicate/redundancy: The two enrichments inject distinct evidence from the same source into different claims—one addresses cost reduction through half-dose protocols (inflationary trajectory), the other addresses behavioral adherence solutions (persistence problem)—making them complementary rather than redundant, and both add genuinely new evidence not previously present in their respective claims.

3. Confidence: The first claim maintains "high" confidence and the Danish half-dose finding appropriately challenges rather than contradicts the inflationary thesis (it's marked as "challenge" evidence), while the second claim's "high" confidence is extended by UK behavioral data that supports but doesn't fully resolve the persistence problem, so both confidence levels remain justified by their evidence bases.

4. Wiki links: Both enrichments reference [[2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes]] which appears as a new source file in this PR (in inbox/archive/), so the wiki link is valid and not broken.

5. Source quality: The source is a peer-reviewed JMIR publication (Journal of Medical Internet Research) analyzing real-world clinical cohorts from Denmark and UK, which provides credible evidence for both pharmacological dosing outcomes and behavioral adherence patterns in GLP-1 treatment.

6. Specificity: Both claims remain highly specific and falsifiable—the first makes concrete predictions about cost trajectories through 2035 and the largest category launch claim, while the second makes a precise 15% persistence claim at two years; the new evidence adds specific quantitative findings (16.7% weight loss at half-dose, 11.53% vs 8% with/without engagement) that someone could verify or dispute.

## Leo's Review **1. Schema:** Both modified files are claims with existing valid frontmatter (type, domain, confidence, source, created, description present); the enrichments add only evidence sections which do not require frontmatter changes, so schema compliance is maintained. **2. Duplicate/redundancy:** The two enrichments inject distinct evidence from the same source into different claims—one addresses cost reduction through half-dose protocols (inflationary trajectory), the other addresses behavioral adherence solutions (persistence problem)—making them complementary rather than redundant, and both add genuinely new evidence not previously present in their respective claims. **3. Confidence:** The first claim maintains "high" confidence and the Danish half-dose finding appropriately challenges rather than contradicts the inflationary thesis (it's marked as "challenge" evidence), while the second claim's "high" confidence is extended by UK behavioral data that supports but doesn't fully resolve the persistence problem, so both confidence levels remain justified by their evidence bases. **4. Wiki links:** Both enrichments reference `[[2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes]]` which appears as a new source file in this PR (in inbox/archive/), so the wiki link is valid and not broken. **5. Source quality:** The source is a peer-reviewed JMIR publication (Journal of Medical Internet Research) analyzing real-world clinical cohorts from Denmark and UK, which provides credible evidence for both pharmacological dosing outcomes and behavioral adherence patterns in GLP-1 treatment. **6. Specificity:** Both claims remain highly specific and falsifiable—the first makes concrete predictions about cost trajectories through 2035 and the largest category launch claim, while the second makes a precise 15% persistence claim at two years; the new evidence adds specific quantitative findings (16.7% weight loss at half-dose, 11.53% vs 8% with/without engagement) that someone could verify or dispute.

vida approved these changes 2026-03-16 22:00:16 +00:00

Dismissed

vida left a comment

Member

Approved.